Capsaicin Effect on Cytokines Profile in Dyslipidemia

Effect of Administration of Capsaicin on Inflammatory Cytokines Profile(TNFα , IL - 1β , IL - 6, IL -8 , MIP - 1β) in Individuals With Dyslipidemia.

Status

UNKNOWN

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02823912

Enrollment

Registered

2016-07-06

Start date

2016-10-31

Completion date

2017-10-31

Last updated

2016-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia, Overweight or Obesity

Keywords

Capsaicin, Dyslipidemia, Inflammatory cytokines

Brief summary

The increased mortality from cardiovascular disease has a significant impact on the population, and the prevalence of these diseases it become one of the major problems, since it is the leading cause of mortality and 1 in 3 Mexicans suffer from cardiovascular disease according ENSANUT; the above is attributed to the increase of diseases associated with an inflammatory process accelerated as obesity, dyslipidemia, hypertension (SAH) and diabetes mellitus (DM). The cholesterol is a major risk factor in the development of cardiovascular disease, and in turn increases the chances of death; however, the treatment of choice is based on changes in lifestyle, which for most people are difficult to maintain long-term. As for the drug therapy treated with drugs many people do not achieve their therapeutic goals, and therefore the inflammatory condition that underlies this disease remains. Recent studies have focused on the possible role of capsaicin in the inflammatory state through the agonistic effect it has on TRPV1. It has demonstrated the antiinflammatory activity of capsaicin to enhance inflammation by free fatty acids (FFA) and reducing the expression of certain genes involved in this process induced. Capsaicin is a natural choice and well tolerated with few side effects limited to the gastrointestinal tract such as dyspepsia and intestinal irregularity, for the above is of interest to evaluate the effect of capsaicin on the profile of inflammatory cytokines in individuals with dyslipidemia.

Detailed description

It will conduct a clinicala trial, double - blind, randomized and placebo control group. Female and male patients, with dyslipidemia. Two groups will be formed with 17 patients each (capsaicin 150 mg per day or Magnesia calcinada). At the beginning and end of the intervention clinical and laboratory determination. The data obteined were analyzed using SPSS statistical software version 22. It was considered statistically significant at p \<0.05

Interventions

DRUGCapsaicin

DRUGMagnesia calcinada

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

25 Years to 45 Years

Healthy volunteers

Inclusion criteria

* diagnosis of dyslipidemia at the time of screening * BMI of 25 kg /m2 to 34.9 kg / m2 * Without drug treatment in the last three months * Signature of consent information in writing

Exclusion criteria

* Pregnant or lactating * Total cholesterol ≥ 239 mg / dL, ≥400 TG, LDL-C ≥139 * Other inflammatory diseases * consumption of some type of supplement * Diagnosis or history of kidney or liver disease ∞ History of hypersensitivity to the compounds used in the study

Design outcomes

Primary

Measure	Time frame	Description
Inflammatory cytokines profile	90 days	TNFα

Secondary

Measure	Time frame	Description
Lipids profile	90 days	total cholesterol

Contacts

Primary ContactLeonel Garcia Benavides, PhD

drleonelgb@hotmail.com10585200

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026